Active clinical trials for "Melanoma"

The aim of this trial is to identify biomarkers and genetic predisposition for the development of immune checkpoint related colitis.

Within the first year after diagnosis, data on employment and quality of life will be collected and evaluated in patients with malignant melanoma

Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples. No patients will be enrolled in this study. Data will be collected for approximately 6 months.

The use of MDS to access the presence of melanoma in the skin.

The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma and a group of hospitalized control patients.

The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted in the same patient population as well as using the same melphalan dosing as proposed in this study. This expanded access protocol will provide an experimental alternative treatment option for both physicians and patients until the Delcath CS-PHP System receives marketing approval.

The use of MDS to access the presence of melanoma in the skin.

The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.

The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.